The U.S. Food and Drug Administration (FDA) has approved Aczone (dapsone) Gel, 5% for the topical treatment of acne vulgaris in patients 12 years and older.
Aczone is an aqueous topical gel containing 5% dapsone. Aczone has been shown to achieve statistically significant percent reduction in the number of acne lesions and better success rate on the Global Acne Assessment Score. Like many acne treatments, the mechanism of action of dapsone gel in treating acne vulgaris is not known.
The most common adverse events reported from controlled clinical trials include oiliness/peeling, dryness, and erythema.
Patients will need to be screened to detect if they are predisposed to one type of anemia (hemolytic anemia) because of a specific enzyme deficiency, G6PD (Glucose 6-phosphate dehydrogenase) deficiency. Safety of Aczone Gel, has not been fully evaluated in patients with G6PD deficiency. Although not observed in the clinical trials with topical dapsone, serious adverse reactions have been reported with oral use of dapsone.
See also
2 comments ↓
When can I prescribe this product ?
i have been using this product for a year prescribed to me by my dermatologist it has helped allot and it also cleans my face i use it with NeoBenz Micro Wash and together they form a great team however i also noticed i have better skin when i eat healthier and go to sleep earlier and have less stress skin looks better
Leave a Comment